vs
Amphastar Pharmaceuticals, Inc.（AMPH）とCOPT DEFENSE PROPERTIES（CDP）の財務データ比較。上の社名をクリックして会社を切り替えられます
COPT DEFENSE PROPERTIESの直近四半期売上が大きい（$197.4M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.1倍）。COPT DEFENSE PROPERTIESの純利益率が高く（20.0% vs 13.3%、差は6.6%）。COPT DEFENSE PROPERTIESの前年同期比売上増加率が高い（7.6% vs -1.8%）。COPT DEFENSE PROPERTIESの直近四半期フリーキャッシュフローが多い（$288.9M vs $24.6M）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs 1.1%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
COPTディフェンス・プロパティーズは不動産投資信託で、主にワシントンD.C.大都市圏近郊のオフィスビルに投資し、米国政府や国防産業関連企業を主なテナントとしています。2024年12月31日時点で、総面積1650万平方フィートのオフィスビル164棟と、総面積590万平方フィートの単一テナント型データセンター31棟を保有しています。
AMPH vs CDP — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $197.4M |
| 純利益 | $24.4M | $39.4M |
| 粗利率 | 46.8% | — |
| 営業利益率 | 19.4% | 19.9% |
| 純利益率 | 13.3% | 20.0% |
| 売上前年比 | -1.8% | 7.6% |
| 純利益前年比 | -35.7% | 8.0% |
| EPS（希薄化後） | $0.51 | $0.32 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $197.4M | ||
| Q3 25 | $191.8M | $188.8M | ||
| Q2 25 | $174.4M | $189.9M | ||
| Q1 25 | $170.5M | $187.9M | ||
| Q4 24 | $186.5M | $183.4M | ||
| Q3 24 | $191.2M | $189.2M | ||
| Q2 24 | $182.4M | $187.3M | ||
| Q1 24 | $171.8M | $193.3M |
| Q4 25 | $24.4M | $39.4M | ||
| Q3 25 | $17.4M | $43.7M | ||
| Q2 25 | $31.0M | $40.2M | ||
| Q1 25 | $25.3M | $36.2M | ||
| Q4 24 | $38.0M | $36.5M | ||
| Q3 24 | $40.4M | $37.4M | ||
| Q2 24 | $37.9M | $36.4M | ||
| Q1 24 | $43.2M | $33.7M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 19.9% | ||
| Q3 25 | 13.2% | 22.5% | ||
| Q2 25 | 24.2% | 21.0% | ||
| Q1 25 | 21.9% | 19.1% | ||
| Q4 24 | 24.2% | 19.7% | ||
| Q3 24 | 29.8% | 19.8% | ||
| Q2 24 | 30.3% | 19.4% | ||
| Q1 24 | 27.9% | 17.5% |
| Q4 25 | 13.3% | 20.0% | ||
| Q3 25 | 9.0% | 23.2% | ||
| Q2 25 | 17.8% | 21.1% | ||
| Q1 25 | 14.8% | 19.3% | ||
| Q4 24 | 20.4% | 19.9% | ||
| Q3 24 | 21.1% | 19.8% | ||
| Q2 24 | 20.8% | 19.4% | ||
| Q1 24 | 25.1% | 17.4% |
| Q4 25 | $0.51 | $0.32 | ||
| Q3 25 | $0.37 | $0.37 | ||
| Q2 25 | $0.64 | $0.34 | ||
| Q1 25 | $0.51 | $0.31 | ||
| Q4 24 | $0.74 | $0.31 | ||
| Q3 24 | $0.78 | $0.32 | ||
| Q2 24 | $0.73 | $0.31 | ||
| Q1 24 | $0.81 | $0.29 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $275.0M |
| 総負債低いほど良い | $608.7M | $2.8B |
| 株主資本純資産 | $788.8M | $1.5B |
| 総資産 | $1.6B | $4.7B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 1.83× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $275.0M | ||
| Q3 25 | $276.2M | $23.7M | ||
| Q2 25 | $231.8M | $21.3M | ||
| Q1 25 | $236.9M | $24.3M | ||
| Q4 24 | $221.6M | $38.3M | ||
| Q3 24 | $250.5M | $34.5M | ||
| Q2 24 | $217.8M | $100.4M | ||
| Q1 24 | $289.6M | $123.1M |
| Q4 25 | $608.7M | $2.8B | ||
| Q3 25 | $608.6M | $2.4B | ||
| Q2 25 | $607.7M | $2.4B | ||
| Q1 25 | $603.9M | $2.4B | ||
| Q4 24 | $601.6M | $2.4B | ||
| Q3 24 | $596.4M | $2.4B | ||
| Q2 24 | $586.9M | $2.4B | ||
| Q1 24 | $594.0M | $2.4B |
| Q4 25 | $788.8M | $1.5B | ||
| Q3 25 | $776.7M | $1.5B | ||
| Q2 25 | $757.5M | $1.5B | ||
| Q1 25 | $751.3M | $1.5B | ||
| Q4 24 | $732.3M | $1.5B | ||
| Q3 24 | $727.7M | $1.5B | ||
| Q2 24 | $713.3M | $1.5B | ||
| Q1 24 | $672.4M | $1.5B |
| Q4 25 | $1.6B | $4.7B | ||
| Q3 25 | $1.7B | $4.4B | ||
| Q2 25 | $1.6B | $4.3B | ||
| Q1 25 | $1.6B | $4.3B | ||
| Q4 24 | $1.6B | $4.3B | ||
| Q3 24 | $1.5B | $4.2B | ||
| Q2 24 | $1.5B | $4.2B | ||
| Q1 24 | $1.6B | $4.2B |
| Q4 25 | 0.77× | 1.83× | ||
| Q3 25 | 0.78× | 1.62× | ||
| Q2 25 | 0.80× | 1.63× | ||
| Q1 25 | 0.80× | 1.62× | ||
| Q4 24 | 0.82× | 1.60× | ||
| Q3 24 | 0.82× | 1.61× | ||
| Q2 24 | 0.82× | 1.61× | ||
| Q1 24 | 0.88× | 1.63× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $309.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $288.9M |
| FCFマージンFCF / 売上 | 13.4% | 146.4% |
| 設備投資強度設備投資 / 売上 | 4.5% | 10.7% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 7.87× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $501.5M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $309.9M | ||
| Q3 25 | $52.6M | $68.6M | ||
| Q2 25 | $35.6M | $87.9M | ||
| Q1 25 | $35.1M | $72.1M | ||
| Q4 24 | $29.0M | $331.0M | ||
| Q3 24 | $60.0M | $65.1M | ||
| Q2 24 | $69.1M | $93.8M | ||
| Q1 24 | $55.3M | $71.0M |
| Q4 25 | $24.6M | $288.9M | ||
| Q3 25 | $47.2M | $62.9M | ||
| Q2 25 | $25.0M | $84.5M | ||
| Q1 25 | $24.4M | $65.1M | ||
| Q4 24 | $16.6M | $299.6M | ||
| Q3 24 | $46.2M | $61.0M | ||
| Q2 24 | $63.1M | $88.4M | ||
| Q1 24 | $46.5M | $57.9M |
| Q4 25 | 13.4% | 146.4% | ||
| Q3 25 | 24.6% | 33.3% | ||
| Q2 25 | 14.3% | 44.5% | ||
| Q1 25 | 14.3% | 34.7% | ||
| Q4 24 | 8.9% | 163.3% | ||
| Q3 24 | 24.1% | 32.3% | ||
| Q2 24 | 34.6% | 47.2% | ||
| Q1 24 | 27.1% | 30.0% |
| Q4 25 | 4.5% | 10.7% | ||
| Q3 25 | 2.8% | 3.0% | ||
| Q2 25 | 6.1% | 1.8% | ||
| Q1 25 | 6.3% | 3.7% | ||
| Q4 24 | 6.7% | 17.1% | ||
| Q3 24 | 7.2% | 2.1% | ||
| Q2 24 | 3.3% | 2.9% | ||
| Q1 24 | 5.1% | 6.8% |
| Q4 25 | 1.35× | 7.87× | ||
| Q3 25 | 3.03× | 1.57× | ||
| Q2 25 | 1.15× | 2.19× | ||
| Q1 25 | 1.39× | 1.99× | ||
| Q4 24 | 0.76× | 9.08× | ||
| Q3 24 | 1.48× | 1.74× | ||
| Q2 24 | 1.82× | 2.58× | ||
| Q1 24 | 1.28× | 2.11× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
CDP
セグメントデータなし
